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Background: Accumulating evidences suggest that aldose reductase (AR) inhibitors and advanced glycation end
product (AGE) formation inhibitors may prevent chronic hyperglycemia-induced long-term complication in
diabetes. Transforming growth factor-beta1 (TGF-β1) plays an important role in the development of diabetic
nephropathy. Allium species have been utilized in folk medicine throughout the world for the treatment of various
physical disorders. However, the benefits of Allium victorialis (A. victorialis) against diabetic complications, especially
nephropathy, have yet to be explored. In the present study, we investigated the protective effect of the
compounds isolated from A. victorialis leaf on diabetic nephropathy.
Methods: In vitro AR activity, AGEs formation, and AGE-receptor for AGEs (RAGE) binding in human RAGE
(hRAGE)-overexpressing cells were tested. High glucose-induced transforming growth factor-beta1 (TGF-β1)
expression was also examined in mouse kidney mesangial cells (MMCs) cultured under high glucose.
Results: Of the isolated eight compounds from A. victorialis leaf extracts tested, quercitrin exhibited the most
pronounced inhibitory effects on AR activity (IC50 value of 0.17 μM) and AGEs formation (IC50 value of 4.20 μM).
Furthermore, quercitrin disrupted AGE-RAGE binding in a concentration-dependent manner in hRAGE-overexpressing
cells. Additionally, of the eight compounds tested, ferulic acid significantly reduced high glucose-induced TGF-β1
expression and secretion in MMCs.
Conclusions: Our results suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR
activity in rat lenses and AGE formation. Further, ferulic acid reduces TGF-β1 mRNA expression and secretion in MMCs
under diabetic conditions. Thus, A. victorialis is a good candidate for the development of treatments for diabetic
nephropathy.
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Chronic hyperglycemia is the most common feature of
all forms of diabetes mellitus, and it accelerates the in-
duction of aldose reductase (AR, EC 1.1.1.21) and the ir-
reversible formation of advanced glycation end products
(AGEs), which play important roles in the pathogenesis
of diabetic complications [1]. Diabetic nephropathy is a
major complication of diabetes mellitus, and although
the mechanism of glomerulosclerosis still remains un-
clear, the irreversible formation of AGEs, polyol accu-
mulation, and oxidative stress have been considered the
major causes of diabetic nephropathy [2]. AR, the first
rate-limiting enzyme in the polyol pathway, is present
in the eyes, kidneys, and other tissues affected by
diabetic complications. Increased glucose enters the
polyol pathway, where it is reduced by AR to sorbitol
[2,3]. AR inhibitors (ARIs), such as epalrestat, 3,3-
tetramethyleneglutaric acid (TMG), and fidarestat,
have been developed, and some have been revealed to
prevent diabetic nephropathy in animal models or pa-
tients [3-7]. ARIs from natural products have been
found to prevent or delay the development of diabetic
complications in animal models [8-10].
Transforming growth factor-beta 1 (TGF-β1) is a
multifunctional cytokine that plays important roles in
cell proliferation, wound healing, differentiation, apop-
tosis, and the immune response in several cells [11]. In
particular, TGF-β1 is a key mediator of diabetic ne-
phropathy that increases the levels of extracellular
matrix (ECM) proteins, such as collagen I and IV, lam-
inin, and fibronectin, in the glomeruli [11]. In addition,
TGF-β has been identified as a critical regulator and me-
diator of pathophysiological processes of ocular tissue
development or repair. TGF-β–mediated signaling is in-
volved in the progression of diabetic nephropathy, and
high levels of TGF-β are found in diabetic kidneys.
Natural products and their active constituents have
been reportedly used for the treatment of diabetes and
diabetic complications [10]. The genus Allium comprises
more than 600 different species distributed throughout
North America, North Africa, Europe, and Asia. Many
Allium species have been utilized in folk medicine
throughout the world for the treatment of various
physical disorders such as burns, wounds, headaches,
chest colds, and rheumatism [12]. Allium victorialis var.
platyphyllum (Liliaceae), one of the most popular Allium
species, is an edible perennial herb widely distributed on
Ulleung Island and Mt. Hambeak of the Korean Peninsula.
Recently, Allium victorialis (A. victorialis) has received
much attention owing to its diverse and potentially signifi-
cant pharmacological properties including antiarterio-
sclerotic, anticancer, antioxidant, antidiabetic, antiobesity,
antineuroinflammatory, hepatoprotective, and nephro-
protective effects [12-21].In this paper, we examined the effects of eight com-
pounds (1–8) isolated from A. victorialis leaf on AR ac-
tivity, AGE formation, and TGF-β1 mRNA expression
and protein secretion in mouse glomerular mesangial
cells (MMCs) cultured under diabetic conditions. Fur-
thermore, binding between AGE and receptor for AGE
(RAGE) in human RAGE (hRAGE)-overexpressing
MMCs was analyzed, and the most active compound
was identified. These results show that single com-
pounds from A. victorialis leaf extracts have preventive
effects against diabetic nephropathy and may be useful
as candidates for preclinical study in the treatment of
diabetic nephropathy.Methods
Plant materials and chemicals
The leaf of A. victorialis were purchased from a com-
mercial supplier in Goryung, (Gyeongbuk, Korea, in
January, 2005) and identified by Prof. K-R Park in the
Department of Herbology, The Medical Research center
for Globalization of Herbal Formulation, Daegu Haany
University. A herbarium voucher specimen (no. KIOM-
ALVI) has been deposited at the Herbarium of the
Diabetic Complications Research Group, Korea Institute
of Oriental Medicine. Antibodies were purchased from
Cell Signaling (Beverly, MA) and Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). All other reagents were obtained
from Sigma-Aldrich (St. Louis, MO). Reagents used for
cell culture were purchased from GIBCO-BRL (Grand
Island, NY).General experimental procedures
Optical rotations were measured on a JASCO P-2000
digital polarimeter. Hydrogen 1 (300 MHz) and carbon
13 nuclear magnetic resonance (NMR; 75 MHz) spectra
were obtained using a Bruker DRX-300 spectrometer
with tetramethylsilane as an internal standard. Two-
dimensional-NMR experiments (correlation spectros-
copy, heteronuclear multiple-quantum correlation, and
heteronulear multiple bond correlation) were run on a
Bruker Avance 500 NMR spectrometer. Electrospray
ionization mass spectrometry spectra were recorded on
a Shimadzu liquid chromatography-mass spectrometry-
ion trap-time of flight spectrometer. Column chroma-
tography was performed using silica gel (70–230 mesh,
Merck), YMC-gel ODS-A (12 nm, S-75 μm, YMC), and
Sephadex LH-20 (Amersham Pharmacia Biotech). Thin-
layer chromatography was performed on pre-coated sil-
ica gel 60 F254 (0.25 mm, Merck) and RP-18 F254s plates
(0.25 mm, Merck). Spots were detected by utraviolet
light (254 nm) and spraying with 10% H2SO4 followed
by heating.
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The air-dried leaf of A. victorialis (4.0 kg) were extracted
with 50% EtOH (36 L) at 60°C for 5 h, filtered, and con-
centrated to yield a 50% EtOH extract (1.0 kg). This ex-
tract (1.0 kg) was suspended in H2O (4 L) and then
partitioned successively with EtOAc (3 × 4.0 L) and n-
BuOH (3 × 4.0 L) to afford EtOAc- (13 g) and n-BuOH-
soluble fractions (258 g), respectively. The EtOAc- (12 g)
and n-BuOH-soluble fractions (250 g) were subjected to
a series of chromatographic techniques including silica gel,
YMC RP-18, and Sephadex LH-20 column chromatogra-
phies, leading to the isolation of eight compounds (1−8,
Table 1), Kaempferol 3,7,4’-O-β-D-triglucopyranoside
(1, 280 mg), Kaempferol 3,7-O-β-D-diglucopyranoside
(2, 66 mg), kaempferol 3,4’-O-β-D-diglucopyranoside
(3, 70 mg), quercitrin (4, 10 mg), kaempferol (5, 24 mg),
quercetin (6, 45 mg), 4-hydroxycinnamic acid (7, 4.3 mg),
and ferulic acid (8, 10 mg).
Rat lens AR activity
AR activity was measured as described previously [9,22].
All animal procedures were approved by the Korea Institute
of Oriental Medicine Institutional Animal Care Committee
on animal care at our institute and conducted according to
institutional guidelines. Rat lenses were isolated from the
eyes of 8-week-old Sprague–Dawley rats (Orient Co.,
Seongnam, Korea) and homogenized in 12 volumes of 150
mM sodium phosphate buffer (pH 6.2) and 10 mM 2-
mercaptoethanol. The homogenate was centrifuged at
14,000 rpm for 30 min, and the supernatant was used as
crude rat lens AR. The incubation mixture contained 150
mM sodium phosphate buffer, 0.15 mM nicotinamide ad-
enine dinucleotide phosphate (NADPH), 10 mM DL-glyc-
eraldehyde as a substrate, and 700 μg/ml of enzyme
substrate, with or without compounds or positive control,Table 1 Inhibitory effect of extracts, fractions, and compound
No. Extracts, fractions, and isolated compounds Mw
1 Kaempferol 3,7,4’-O-β-D-triglucopyranoside 772.66
2 Kaempferol 3,7-O-β-D-diglucopyranoside 610.52




7 4-Hydroxycinnamic acid 164.16
8 Ferulic acid 194.16
9 A. victorialis 50% EtOH
10 A. victorialis EtOAc
11 A. victorialis BuOH
12 Tetramethyleneglutaric acid 186.20
13 Aminoguanidine 74.1in a total volume of 1.0 ml. The reaction was initiated by
the addition of NADPH at 37°C and stopped by the
addition of 0.15 ml of 0.5 N HCl. Next, 0.5 ml of 6 M
NaOH containing 10 mM imidazole was added, and the so-
lution was heated at 60°C for 15 min to convert NADP to a
fluorescent product. The fluorescence (ex. 360 nm/ em.
460 nm) was assayed using a spectrofluorometric detector
(Synergy HT, Bio-Tek, Winooski, VT). The concentration
of each test sample that inhibited activity by 50% (IC50)
was estimated from the least-squares regression line of the
logarithmic concentration plotted against the remaining
activity.
Determination of AGEs formation
AGEs formation assay was performed as previously de-
scribed [23,24]. Bovine serum albumin (BSA, 10 mg/ml,
Sigma-Aldrich) in 50mM phosphate buffer (pH 7.4) with
containing 0.02% sodium azide to prevent bacterial
growth was added to 0.2 M fructose and glucose. The
reaction mixture was then mixed with compounds or
aminoguanidine (AG, Sigma-Aldrich). After incubating
at 37°C for 7 days, the fluorescent reaction products
were assayed on a spectrofluorometric detector (BIO-
TEK, Synergy HT, Ex: 350 nm/Em: 450 nm). AGEs assay
was performed in quadruplicate. The concentration of
each test sample giving 50% inhibition of the activities
(IC50) was estimated from the least-squares regression
line of the logarithmic concentration plotted against the
remaining activity.
Cell Cultures
Mouse kidney mesangial cells (SV40 MES13, MMC) were
obtained from the American Type Culture Collection
(#CRL-1927, Rockville, MD) and cultured in Dulbecco's
modified Eagle's medium:F-12 (3:1) supplemented with 14s isolated from A. victorialis on AR and AGEs formation
AR IC50 AGEs IC50
>50 μM >100 μM
>50 μM 56.44±1.39 μM
9.77±0.33 μM 59.66±1.22 μM
0.17±0.10 μM 4.20±0.04 μM
1.10±0.63 μM 36.01±1.40 μM
3.61±0.19 μM 27.10±0.11 μM
>50 μM 9.92±0.11 μM
>50 μM 7.50±0.20 μM
>10 μg/ml >75 μg/ml
7.53±0.02 μg/ml 30.13±1.68 μg/ml
>10 μg/ml >75 μg/ml
5.07±0.06 μM (0.94±0.01 μg/ml) -
- 1.03±0.07 mM (76.47±4.81 μg/ml)
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and 5% fetal bovine serum. Cells were routinely grown to
confluence in a humidified 37°C, 5% CO2 incubator.
RNA extraction and semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR) analysis
Total cellular RNA was extracted with TRIzol (Invitrogen,
Carlsbad, CA), quantified by measuring the absorbance at
260 nm, and stored at −80°C until analysis. The expression
of TGF-β1 and GAPDH mRNAs was detected by RT-PCR
analysis. The extracted RNA (1 μg) was subjected to a
reverse transcriptase reaction with the Maxime RT premix
(Intron, Daejeon, Korea) at 42°C for 60 min and 72°C
for 10 min. Subsequently, semi-quantitative PCR was
performed with Accupower® PCR premix (Intron, Daejeon,
Korea). The primer sequences were as follows: mouse
TGF-β1 (sense) 5’- TGA ACC AAG GAG ACG GAA TAC
AGG -3’, (anti-sense) 5'- GCC ATG AGG AGC AGG AAG
GG -3’ and mouse GAPDH (sense) 5’- ACG GCA AAT
TCA ACG GCA CAG -3’, (anti-sense) 5’- AGA CTC CAC
GAC ATA CTC AGC AC -3’. Aliquots of PCR products
were electrophoresed on 1.2% agarose gels and visualized
after ethidium bromide staining.
Determination of secreted TGF-β1 expression in MMCs
using enzyme-linked immunosorbent assay (ELISA)
The levels of TGF-β1 in the medium were determined
as described previously [9]. The medium was replaced
with serum-free medium containing compound under
high glucose conditions for 24 h. This medium was then
harvested and TGF-β1 was activated by treatment with
1 N HCl (0.1 ml/0.5 ml of conditioned media) for 10Figure 1 Structures of the compounds (1–8) isolated from the leaf ofmin at room temperature, then 0.1 ml 1.2 N NaOH/0.5
M HEPES was added. Quantikine mouse TGF-β1 ELISA
(R&D systems, Minneapolis, MN) was performed ac-
cording to the manufacturer’s protocol, and the TGF-β1
levels were normalized to those of total protein. Medium
without cells that had been incubated under the same
conditions was used as a control for the ELISA.Detection of live cell-based AGE-BSA/RAGE binding
AGE-BSA/RAGE binding in the cells was determined as
described previously [23]. Briefly, Alexa 488 labeling of
AGE-BSA was performed using the Alexa Fluor® 488
protein labeling kit (Molecular Probes, Eugene, OR). For
the binding assay, human RAGE-overexpressing cells
(1×104) were seeded onto a 96-well assay plate with a
clear bottom lid and black plate (Corning, NY) and incu-
bated with serum-free media for 24 h. Before binding,
3% BSA was added for 30 min to block non-specific
binding. Cells were treated with 5 μg of Alexa Fluor
488-labeled AGE-BSA in a total volume of 100 μl
serum-free medium and incubated in the dark for 6 h in
a 5% CO2 humidified atmosphere at 37°C. Compounds
were added after the addition of AGE-BSA-Alexa Fluor
488 to hRAGE-overexpressing cells. The non-specific
binding of AGE-BSA-Alexa Fluor 488 to cell surface
proteins other than hRAGE was compared by incubating
cells with untreated cells (blank). After binding, 100 μl
Opti-MEM were added to the washed plates, and the
plates were then analyzed using a microtiter plate reader
(Bio-Tek, Winooski, VT) with excitation and emission
wavelengths of 485 and 528 nm, respectively.A. victorialis.
Figure 2 Inhibitory effects of the isolated compounds on AGE-
BSA/hRAGE binding in hRAGEoverexpressing MMCs. Effects of
the compounds (A. Kaempferol (5); B. Quercitrin (4); C. Quercetin (6))
on AGE/hRAGE binding were quantified by a fluorescence detector.
Data are presented as the mean ± standard error of the mean (S.E.M.;
n=4). ***p<0.001 vs. untreated cells; ##p<0.01 vs. cells treated with only
Alexa Fluor 488- labeled AGE-BSA.
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Data are expressed as mean ± S.E.M. of multiple experi-
ments. Paired Student's t-tests were used to compare
two groups, or analysis of variance with Tukey’s was
used for multiple comparison tests using PRISM soft-
ware (Graph Pad, San Diego, CA). Values of p < 0.05
were considered statistically significant.
Results and discussion
Structure elucidation of compounds
The EtOAc- and n-BuOH–soluble fractions were
subjected to a series of chromatographic techniques,
leading to the isolation of eight known compounds (1–8)
(Figure 1). These compounds were identified as
kaempferol 3,7,4′-O-β-D-triglucopyranoside (1), ka-
empferol 3,7-O-β-D-diglucopyranoside (2), kaempferol
3,4'-O-β-D-diglucopyranoside (3), quercitrin (4), ka-
empferol (5), quercetin (6), 4-hydroxycinnamic acid
(7), and ferulic acid (8) by comparing their physicochemi-
cal and spectral data to those in the literature [25-31].
Rat lens AR activity, AGE formation, and AGE/RAGE-
binding in hRAGE-overexpressing cells
ARIs suppressing the hyperglycemia-induced polyol
pathway have been identified as potential therapeutic
candidates in the treatment and prevention of diabetic
complications. The IC50 values of compounds (Table 1)
in this assay were comparable to that those of known
ARIs, such as TMG, which suggested that the com-
pounds and extracts appeared to have an inhibitory ef-
fect on AR activity. Among the compounds, quercitrin
(4), kaempferol (5), and quercetin (6) were significantly
more potent than the previously known positive control,
TMG. Previous research also demonstrated that flavo-
noids such as quercetin and myricitrin are effective in-
hibitors of lens AR [28]. We previously reported that
quercitrin gallate also inhibits AR activity and xylose-
induced lens opacity and oxidation [25]. Kaempferol and
its prenylated derivatives are reported to be aldolase in-
hibitor [32]. Kaempferol 3,4’-O-β-D-diglucopyranoside
(3) (IC50 = 9.77 ± 0.33 μM) and the A. victorialis
EtOAc- soluble fraction (IC50 = 7.53 ± 0.02 μg/ml)
inhibited AR activity. Although, IC50 level of EtOAc-
soluble fraction was higher than TMG (0.94±0.01 μg/
ml), among the extracts, it has the inhibitory effects on
AGEs formation (IC50 =30.13±1.68 μg/ml; AG, IC50 =
76.47±4.81 μg/ml). Previous research indicated that ge-
nistein has inhibitory effects of AR activity in vitro,
AGEs formation, and AGE-RAGE binding in hRAGE-
overexpressing cells [9,23]. Next, we examined the in-
hibitory effects of compounds and extracts on AGEs
formation (Table 1). Quercitrin (4) (IC50 = 4.20 ± 0.04 μM)
and ferulic acid (8) (IC50 = 7.50 ± 0.20 μM) exhibited in-
hibitory effects on AGEs formation. Furthermore,because of the pronounced inhibitory effect of the three
compounds (4, 5, and 6) on AR and AGEs formation,
AGE-RAGE binding assays were performed in hRAGE-
overexpressing cells (Figure 2). Among the compounds,
quercitrin (4) significantly inhibited AGE-RAGE binding
in hRAGE-overexpressing cells. Although quercitrin (4)
has been tested on ARI effect [28], this compound has
never been examined for the AGE-RAGE binding assay
in hRAGE-overexpressing cells up to data. Quercitrin
has anti-inflammatory effect through the inhibition of
the NF-kappa B pathway and it shows potential anti-
cancer effect, including cell cycle regulation and tyrosine
kinase inhibition [33,34].
Figure 4 Inhibitory effect of the compounds isolated from A.
victorialis on high glucose-induced TGF-β1 secretion. Quiescent
MMCs were treated with high glucose for 48 h followed by 10 μM
of the compounds (1–8). To determine the amount of secreted TGF-
β1 protein in the medium, ELISAs were performed on MMCs treated
with high glucose. Experiments were done in triplicate on three
separate occasions. Results are the mean ± S.E.M. (n=4). ***p<0.001
vs. untreated cells; ###p<0.001, ##p<0.01, #p<0.05 vs. HG.
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secretion in MMCs
TGF-β1 stimulates the production of ECM proteins such
as fibronectin and collagen and promotes mesangial cell
expansion [35,36]. In diabetic nephropathy, these
changes are associated with the development of base-
ment membrane thickening in the glomeruli [37]. Thus,
TGF-β1 is considered a potential therapeutic target in
diabetic nephropathy and other chronic renal diseases.
To assess which compounds from A. victorialis are in-
volved in the regulation of both TGF-β1 mRNA and
protein levels in MMCs under diabetic conditions, cells
were treated with high glucose in the presence or ab-
sence of single compounds (1–8) for 48 h. As shown in
Figure 3A and B, single compounds (1–8) inhibited
TGF-β1 mRNA expression in high glucose-stimulated
MMCs (***p<0.001, vs. C; ###p<0.001, ##p<0.01, #p<0.05
vs. HG). Furthermore, we demonstrated that compounds
from A. victorialis inhibit high glucose-induced TGF-β1 se-
cretion (Figure 4, ***p < 0.001, vs. C; ###p<0.001, ##p<0.01,
#p<0.05 vs. HG). Among the eight compounds identified
from A. victorialis, ferulic acid (8) displayed the greatest in-
hibitory effect on TGF-β1 expression in MMCs. A previous
study suggested that ferulic acid have protective effects
against diabetic nephropathy by reducing oxidative stress
and inflammation in a rat model of type 2 diabetes [38]. In
the present study, we first demonstrated that the treatmentFigure 3 Inhibitory effect of the compounds isolated from A.
victorialis on high glucose-induced TGF-β1 mRNA expression.
Quiescent MMCs were treated with high glucose for 48 h followed by 10
μM of the compounds (1–8). Kaempferol 3,7,4′-O-β-D-triglucopyranoside
(1), kaempferol 3,7-O-β-D-diglucopyranoside (2), kaempferol 3,4'-O-β-D-
diglucopyranoside (3), quercitrin (4), kaempferol (5), quercetin (6), 4-
hydroxycinnamic acid (7), and ferulic acid (8). TGF-β1 mRNA expression
was determined by relative RT-PCR. Results are the mean ± S.E.M. (n=3).
***p<0.001 vs. untreated cells; ###p<0.001, ##p<0.01, #p<0.05 vs. HG.of MMCs with single compounds from A. victorialis
inhibited high glucose-induced TGF-β1 mRNA expression.
However, toxicology study in vivo is needed to evaluate the
safety of A. victorialis in the drug development.
Conclusion
In summary, our data suggest that active compounds
isolated from A. victorialis leaf exhibit inhibitory effects
on AR activity and AGE formation. Further, ferulic acid
reduces TGF-β1 mRNA expression and secretion in
MMCs under diabetic conditions. Thus, the compounds
isolated from A. victorialis leaf provide some scientific
evidence to support the folk medicinal utilization of A.
victorialis in the treatment of diabetic nephropathy. Fur-
thermore, A. victorialis is a good candidate for the devel-
opment of treatments for diabetic nephropathy.
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